SOURCE: DNAPrint Genomics, Inc.

October 12, 2006 07:00 ET

DNAPrint Genomics to Exhibit Enhanced DNAWitness™ With Retinome™ 2.0 at International Convention of Police Chiefs

SARASOTA, FL -- (MARKET WIRE) -- October 12, 2006 -- DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that the Company will exhibit its products, including DNAWitness™ with Retinome™ 2.0, at the 113th Annual International Association of Chiefs of Police (IACP) Conference in Booth 803 at the Boston Exhibition and Convention Center in Boston, Mass., from Sunday, Oct. 15 through Tuesday, Oct. 17.

"We are extremely pleased to be exhibiting DNAWitness™ and other products at the IACP Conference, which draws 14,000 law enforcement officials from all over the world," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "We look forward to demonstrating how DNAWitness™ can improve their crime scene investigations and enhance their forensic capabilities."

DNAWitness™ employs patent-pending, database-driven methods to infer elements of physical appearance from crime scene DNA and allow forensic investigators to "paint" molecular portraits of a suspect. This innovative forensic technology has already been used in some 130 cases, including the arrest and conviction of Derrick Todd Lee for a series of murders in Louisiana and in New Scotland Yard's search for the so-called Minstead Rapist, a serial sex offender who is operating in an area south of London.

DNAWitness™ derives the percentage of European, East Asian, Native American, and Sub-Saharan African markers in a person's DNA. This ratio for an individual is termed Bio-Geographical Ancestry (BGA), representing general characteristics that can be matched with a searchable database containing information and photographs collected from samples around the world, leading to more accurate identifications of potential criminal suspects.

Retinome™ 2.0 can be combined with the DNAWitness™ product to determine a person's eye color. The Company's patent-pending technology identifies additional markers covering newly identified and informative regions of the human pigmentation gene OCA2. The Company has also developed a Retinome 2.0 capillary electrophoresis kit, which permits investigators to test Retinome 2.0 in their own laboratories, obviating the need to ship their samples to DNAPrint (though that option is still available).

DNAPrint will also be exhibiting its tests for mitochondrial and Y DNA trace samples or mixtures.

For more information, visit www.dnawitness.net.

About the International Association of Chiefs of Police:

The International Association of Chiefs of Police is the world's oldest and largest nonprofit membership organization of police executives, with over 19,000 members in over 100 different countries. The annual IACP gathering enables professionals to examine the state of the police industry through highly rated seminars, forums and technical workshops only offered through IACP. These sessions feature critical issues relevant to today's law enforcement professional and provide solutions to challenges and encourage productive dialogue among peers.

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and better target patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWitness ™, RETINOME™, AncestrybyDNA™ and EuroDNA™. DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Contact Information

  • Company Contact:
    Richard Gabriel
    CEO and President
    941-366-3400

    -or-

    Ron Stabiner
    The Wall Street Group, Inc.
    212-888-4848